#Israel #Tel Aviv #RNA Delivery #Mana.bio #ASGCT 2026

Mana.bio Expands Leadership Team and Unveils Upcoming Presentation

Jewish News International Reports - In a significant stride towards enhancing its strategic capabilities, Mana.bio has recently added three esteemed individuals to its board and advisory team. This biotechnology trailblazer, known for pioneering advancements in targeted RNA delivery via AI-powered lipid nanoparticles (LNP), aims to leverage the new leadership to boost its next phase of growth.

Key Additions to Leadership

Mana.bio has appointed Thaminda Ramanayake as a board member, alongside Michelle Lynn Hall as a board observer and Guy Van Meter as a strategic advisor. Each of these professionals brings with them a wealth of experience and a deep understanding of mRNA therapeutics, LNP delivery systems, and business development, critical for the company’s expansion.

Thaminda Ramanayake

Thaminda Ramanayake joins the board with more than two decades of biopharmaceutical leadership. His background includes significant roles in business development and advancing innovative therapeutics. As a current venture partner at Entrée Bioventures and former CBO at CureVac, Ramanayake has proven instrumental in strategic business transitions and acquisitions, including the crucial acquisition by BioNTech. His influence is expected to guide Mana.bio towards new growth avenues, especially in the context of mRNA medicine.

Michelle Lynn Hall, Ph.D.

Dr. Hall comes on board as a board observer and has been a key figure in biotechnology due to her deep scientific insight and extensive experience. As a co-founder of Entrée Bioventures, she has driven advancements at Eli Lilly and was instrumental in leading Moderna’s molecular modeling team, focusing on the design of mRNAs and LNPs. Her unique combination of scientific understanding and strategic acumen will be invaluable as Mana.bio scales its offerings.

Guy Van Meter

Guy Van Meter, who has served as chief business officer at Adimab for over 15 years, brings unparalleled expertise in therapeutic antibody discovery to Mana.bio. His successful track record in forming over 140 industry partnerships will be essential as Mana.bio seeks to enhance its collaborative efforts in RNA therapeutics.

Upcoming Presentation at ASGCT 2026

Mana.bio will also present groundbreaking data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, slated for May 11–15, 2026, in Boston, Massachusetts.

The presentation, titled "Machine Learning-Driven Design of Lipid Nanoparticles for In Vivo T-Cell Engineering," will showcase Mana.bio's proprietary machine learning platform, highlighting its innovative approach in developing passive-targeted LNPs for T-cell transfection.

This session promises to reveal how Mana.bio’s advanced suite of machine learning models has been successfully trained on an extensive LNP dataset, leading to the identification of unique LNP formulations optimized for T-cell transfection. Results suggest that these formulations can enhance the efficacy of therapeutic CAR constructs, showcasing their potential to improve patient responses in cancer therapies.

The Vision Ahead

Yogev Debbi, Mana.bio's co-founder and CEO, emphasizes the transformative moment that the company is experiencing. “Mana.bio has built an industry-leading platform and established a robust proof of concept. The addition of leaders like Thaminda, Michelle, and Guy will help accelerate our momentum and unlock the full potential of programmable RNA delivery,” he remarked. This strategic expansion is poised to not only strengthen the company’s market position but also broaden access to innovative gene therapies.

About Mana.bio

Founded in Tel Aviv, Israel, Mana.bio is at the forefront of revolutionizing RNA delivery utilizing AI-enabled LNP development. Supported by notable investors, Mana.bio is dedicated to enhancing the efficacy of genetic medicines and improving patient outcomes globally.

For further updates and detailed information about Mana.bio’s pioneering advancements, visit www.mana.bio.